Unger F, Albes J
Abteilung Herzchirurgie, Landeskrankenanstalten Salzburg.
Wien Med Wochenschr. 1990 Jun 15;140(10-11):290-3.
The artificial heart (TAH) has become a clinical reality as a bridging device to staged transplantation. In order to manage one of the limiting factors of transplantation surgery, namely the lack of donor hearts, the use of TAH as a bridging device will be important for the next years. Nevertheless the development of TAH as a permanent prosthesis should be increasingly intensified. Biocompatibility must be the main goal of production. For the present there is no material in sight which fulfills all requirements. It might be possible though, that progresses in the development of synthetic materials will result in non-thrombotic TAH, herewith eliminating the vulnerable spot of TAH.
人工心脏（TAH）作为分期移植的过渡装置已成为临床现实。为解决移植手术的一个限制因素，即供体心脏短缺问题，在未来几年，将TAH用作过渡装置至关重要。然而，应日益加强将TAH开发为永久性假体的工作。生物相容性必须是生产的主要目标。目前还没有一种材料能满足所有要求。不过，合成材料开发方面的进展有可能带来无血栓形成的TAH，从而消除TAH的薄弱环节。
